Javierre Biola M, Esteller Manel, Ballestar Esteban
Cancer Epigenetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Trends Immunol. 2008 Dec;29(12):616-23. doi: 10.1016/j.it.2008.08.008. Epub 2008 Oct 24.
Epigenetic deregulation has become a major topic in biomedical research. Most of the information currently available in the field comes from the study of epigenetic alterations in cancer, particularly in haematological malignancies. The recognition of the epigenetic component of autoimmune diseases in conjunction with the existence of common genes underpinning pathways that are crucial to the development of autoimmunity and haematological cancers, facilitates interaction between these two areas of research. Here, we examine what is presently known from epigenetic studies of autoimmune diseases, how epigenetic alterations in haematological malignancies can be used to better understand mechanisms of epigenetic deregulation and how they might be used in epigenetic therapy to treat autoimmune diseases.
表观遗传失调已成为生物医学研究中的一个主要课题。目前该领域的大部分信息来自对癌症，特别是血液系统恶性肿瘤中表观遗传改变的研究。自身免疫性疾病表观遗传成分的认识，以及支撑自身免疫和血液系统癌症发展关键途径的共同基因的存在，促进了这两个研究领域之间的相互作用。在此，我们探讨目前从自身免疫性疾病的表观遗传学研究中所了解到的情况，血液系统恶性肿瘤中的表观遗传改变如何用于更好地理解表观遗传失调机制，以及它们如何用于表观遗传治疗来治疗自身免疫性疾病。
